- Home
- JGH vs PRQR Comparison
JGH vs PRQR Comparison
Compare JGH & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- PRQR
- Stock Information
- Founded
- JGH 2014
- PRQR 2012
- Country
- JGH United States
- PRQR Netherlands
- Employees
- JGH N/A
- PRQR N/A
- Industry
- JGH Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- JGH Finance
- PRQR Health Care
- Exchange
- JGH Nasdaq
- PRQR Nasdaq
- Market Cap
- JGH 308.3M
- PRQR 309.5M
- IPO Year
- JGH N/A
- PRQR 2014
- Fundamental
- Price
- JGH $13.36
- PRQR $3.56
- Analyst Decision
- JGH
- PRQR Strong Buy
- Analyst Count
- JGH 0
- PRQR 4
- Target Price
- JGH N/A
- PRQR $7.13
- AVG Volume (30 Days)
- JGH 73.9K
- PRQR 531.5K
- Earning Date
- JGH 01-01-0001
- PRQR 11-07-2024
- Dividend Yield
- JGH 9.85%
- PRQR N/A
- EPS Growth
- JGH N/A
- PRQR N/A
- EPS
- JGH N/A
- PRQR N/A
- Revenue
- JGH N/A
- PRQR $20,506,357.00
- Revenue This Year
- JGH N/A
- PRQR $370.31
- Revenue Next Year
- JGH N/A
- PRQR N/A
- P/E Ratio
- JGH N/A
- PRQR N/A
- Revenue Growth
- JGH N/A
- PRQR 306.68
- 52 Week Low
- JGH $10.36
- PRQR $1.61
- 52 Week High
- JGH $12.85
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- JGH 65.09
- PRQR 50.61
- Support Level
- JGH $13.23
- PRQR $3.37
- Resistance Level
- JGH $13.36
- PRQR $3.67
- Average True Range (ATR)
- JGH 0.09
- PRQR 0.19
- MACD
- JGH 0.03
- PRQR -0.06
- Stochastic Oscillator
- JGH 100.00
- PRQR 31.67
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.